Page 1
Page 1
Natural Compounds as Drugs ; Vol. II
This book highlights new trends and aspects in natural products research. It discusses the biodiversity-driven approaches which are now of eminent importance in natural products research, addressing the question why natural products display such a complex chemical information, what makes them often unique and what their characteristics are. Practical questions such as supply of natural substances and production optimization strategies are also covered.
Natural Compounds as Drugs ; Vol. I
This book highlights new trends and aspects in natural products research. It discusses the biodiversity-driven approaches which are now of eminent importance in natural products research, addressing the question why natural products display such a complex chemical information, what makes them often unique and what their characteristics are. Practical questions such as supply of natural substances and production optimization strategies are also covered.
Epigenetic Drug Discovery
This broad view of epigenetic approaches in drug discovery combines methods and strategies with individual targets, including new and largely unexplored ones such as sirtuins and methyl-lysine reader proteins. Presented in three parts - Introduction to Epigenetics, General Aspects and Methodologies, and Epigenetic Target Classes - it covers everything any drug researcher would need in order to know about targeting epigenetic mechanisms of disease.
Drug Metabolism: Current Concepts
The user-friendly text focuses on concepts rather than extraneous details and is supported by many illustrated examples of biotransformations as well as frequent references to current critical reviews and articles highlighting the nature of research objectives in this vibrant area of medicinal development.
Drug design : A conceptual overview
The newer research areas in pharmaceutical sciences, particularly molecular modeling and simulations, prompted a more efficient drug discovery process. Informatics integrated with pharmaceutical sciences (cheminformatics and bioinformatics) became an essential component of drug research. Drug informatics such as genomics and proteomics assists in the Rational Drug Design (RDD). This emerging discipline is known as “Computer-Aided Drug Design" (CADD), which has profound application in RDD. The advanced and adequate practice in drug design informatics is essential for pharmacy graduates. Hence, a companion for acquiring knowledge on these concepts is vital. The students of B. Pharmacy, M. Pharmacy (Pharmaceutical Chemistry, Pharmacology, and Pharmaceutics), biotechnology, biomedical engineering and other interdisciplinary fields may find this book as a reference guide.
Data science, AI, and machine learning in drug development
The confluence of big data, AI, and machine learning has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change. Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R&D, emerging applications of big data, AI and machine learning in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations
Cannabinoids as Therapeutics
this volume concentrates on the diseases, the physiological effects and therapeutic use of cannabinoids. The volume editor Prof. Mechoulam was the first who isolated the prime active constituent (THC, Tetrahydrocannabiol) of marijuana. He published extensively on the pharmacological activities of cannabinoids. The volume is of interest to researchers and clinicians from pharmacology, neuroscience, and medicinal research
Cancer
The last decade has seen a dramatic shift in anticancer drug research towards agents that aim to target selectively key regulatory and signaling processes known to drive tumorigenesis. A number of these newer agents have now been introduced into clinical practice. This volume reviews advances in cancer chemotherapy research over the last 10 years and will be of interest to scientists engaged in drug research in the pharmaceutical industry, biotechnology and startup companies, academia and government institutions. Chapters written by leading experts in their field reflect a range of current medicinal chemistry approaches to small molecule drugs, including anti-hormonal therapy, growth factor inhibition, survival signaling, cell cycle inhibition, anti-angiogenics and anti-nvasives. Each chapter aims to cover the drug target and biological rationale, chemotypes, clinical status and future prospects in this rapidly developing area of drug research.
Biologics in General Medicine
The idea for this book was born during the symposium on biologics organized by ZAFES (Center for Drug Research, Development and Safety at the University of Frankfurt am Main) in September 2005. Highly distinguished researchers special- ing in the field of biologics had gathered together to exchange information on this relatively new subject. Realizing that this symposium was one of the few sources of condensed information on biologics, it became obvious that we had to create a means of informing an interested wider circle of scientists and especially general c- nicians. Therefore, the editors of this book suggested to the researchers at the symposium andalsotoprominent scientists andcliniciansinvolvedinthe developmentand application of biologics as their major field of interest the idea of assembling this compendium. We received an overwhelmingly positive response – thankfully also from the publisher – most being more than willing to support this innovative project with highly relevant chapters on the latest state of the art.
